nirsevimab Archives -

A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that

AZ, Sanofi build case for one-shot RSV antibody

https://pharmaphorum.com/news/az-sanofi-build-case-for-one-shot-rsv-antibody/

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant

After GSK stumble, Pfizer moves forward with RSV vaccine

https://pharmaphorum.com/news/after-gsk-stumble-pfizer-moves-forward-with-rsv-vaccine/

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next

AZ, Sanofi prep filings for one-shot RSV antibody after trial win

https://pharmaphorum.com/news/az-sanofi-prep-filings-for-one-shot-rsv-antibody-after-trial-win/

nirsevimab